Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions
Methamphetamine Use Disorder
Interventions
DRUG

Ketamine

Ketamine 0.50 mg/kg IM will be administered during the first dosing visit, and either 0.50 mg/kg IM or 0.75 mg/kg IM will be administered at the two subsequent dosing visits, depending on the participant's toleration of prior ketamine dose(s). All ketamine dosing visits will be facilitated by a licensed study therapist and clinician (i.e., NP or MD).

BEHAVIORAL

Psychotherapy

Psychotherapy will consist of three 1-hour preparatory talk therapy sessions over the 14 days preceding the first ketamine dosing visit, a 1-hour integration talk therapy session within 1-3 days following each ketamine dosing visit, and a final 1-hour integration talk therapy session about 1 week following the last ketamine visit. All talk therapy visits will be conducted by a licensed study therapist.

Trial Locations (1)

94102

RECRUITING

San Francisco Department of Public Health, San Francicso

All Listed Sponsors
collaborator

San Francisco Department of Public Health

OTHER_GOV

collaborator

California HIV/AIDS Research Program

OTHER

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

Nicky Mehtani, MD, MPH

OTHER